bpc-157 dosing guidelines protocol human BPC-157 Dosing (Common Protocols) πΉ Oral / Subcutaneous β’ 500 mcg daily β’ Duration: 6 weeks πΉ Intramuscular / Peritendinous β’ 1 mg daily β’ Duration: 6 weeks β οΈ Note: Not approved bpc-157 tb-500 protocol bpc-157 dosing
Description
A.ShahA
doi: 10.1136/jmg.2008.057851
The injection site, usually the upper arm or thigh, will be cleaned and prepared
By contrast, PRP and HA benefit from randomized human clinical data (knee osteoarthritis, tendinopathies) that the combo lacks
Drink plenty of water
Potential Risks and Complications Embarking on any surgical path requires a candid understanding of potential pitfalls
